MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.580
-0.210
-5.54%
After Hours: 3.550 -0.03 -0.84% 19:02 08/07 EDT
OPEN
3.800
PREV CLOSE
3.790
HIGH
3.800
LOW
3.560
VOLUME
743.84K
TURNOVER
--
52 WEEK HIGH
11.41
52 WEEK LOW
2.300
MARKET CAP
97.73M
P/E (TTM)
-1.0403
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LJPC stock price target is 10.67 with a high estimate of 20.00 and a low estimate of 4.000.

EPS

LJPC News

More
La Jolla Pharmaceutical EPS misses by $0.13, misses on revenue
La Jolla Pharmaceutical (NASDAQ:LJPC): Q2 GAAP EPS of -$0.57 misses by $0.13. Revenue of $5.81M (+1.9% Y/Y) misses by $2.29M. Shares -3.97% PM. Press Relea
seekingalpha · 2d ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress
SAN DIEGO, California, Aug. 06, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening disea
GlobeNewswire · 2d ago
Merger Arbitrage Mondays - Siemens Healthineers To Acquire Varian Medical Systems
Seeking Alpha - Article · 5d ago
La Jolla Pharmaceutical high on president&CEO appointment
Seeking Alpha · 07/28 20:56
Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer. “Larry has an impressive track record bringing innova
GlobeNewswire · 07/28 20:16
La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc.
-Combined Company Offers Two Innovative Therapies to Treat Patients Suffering from Life-threatening Diseases-SAN DIEGO, California and WATERTOWN, Massachusetts, July 28, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicate
GlobeNewswire · 07/28 20:15
Merger Arbitrage Mondays - A Large Acquisition Ends The Energy Sector Deal Drought
Seeking Alpha · 07/27 10:47
Merger Arbitrage Mondays - Forescout And Advent Settle Their Differences
Seeking Alpha - Article · 07/20 13:18

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About LJPC

La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.
More

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LJPC stock methods without spending real money on the virtual paper trading platform.